TRUSELTIQ® (INFIGRATINIB) CAPSULES
NOTICE OF PERMANENT DISCONTINUATION OF DISTRIBUTION
The purpose of this letter is to inform you that Helsinn Therapeutics (U.S.), Inc. will discontinue distribution of TRUSELTIQ® (infigratinib) capsules as of March 31, 2023, and is now ending all promotional and educational activities.
Importantly, this discontinuation is not for safety or efficacy reasons.
If you are currently taking TRUSELTIQ®, continue taking as directed until instructed by your healthcare provider to make any changes. Please talk to your healthcare provider if you have any questions.
For more information, you may contact Helsinn Therapeutics (U.S.), Inc. at 1-855-541-3495.